Non Small Cell Lung Cancer Clinical Trials

204 studies are recruiting for non small cell lung cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 6

1. Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

   The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-NNS309 and the safety, dosimetry and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-…

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   Uni of Alabama at Birmingham, Birmingham, Alabama

   Locations

   29 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06562192 on ClinicalTrials.gov

2. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

   This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Florida Cancer Specialists - Lake Nona, Orlando, Florida

   Locations

   10 in total

   Run by

   Compass Therapeutics

   See if you can join NCT06150664 on ClinicalTrials.gov

3. Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

   This first-in-human (FIH) study for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicinal products (IMPs) including, but not limited to, cemiplimab…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Kentucky Chandler Medical Center, Lexington, Kentucky

   Locations

   45 in total

   Run by

   BioNTech SE

   See if you can join NCT05142189 on ClinicalTrials.gov

4. ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

   The purpose of this study is to determine if a blood test called circulating tumor DNA (ctDNA) can be used to predict how well patients will respond to treatment and if there is any cancer left after surgery. The investigators will also study if a drug called pembrolizumab can help prevent the canc…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Miami, Miami, Florida

   Run by

   University of Miami

   See if you can join NCT06902272 on ClinicalTrials.gov

5. Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

   This is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC). The study will include participants with a confirmed diagnosis of NSCLC who are deemed to be surgical candidates, or p…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT06088771 on ClinicalTrials.gov

6. Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

   This is a Phase 1b/IIa dose escalation clinical trial determining the recommended phase II dose of SPEDOX-6 in subjects with advanced, therapy-refractory soft-tissue sarcoma (STS); triple-negative breast cancer (TNBC); Non-small cell lung cancer (NSCLC); cervical cancer; ovarian cancer; KRAS mutant…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Chao Family Comprehensive Cancer Center University of California, Irvine, Orange, California

   Run by

   University of California, Irvine

   See if you can join NCT07064018 on ClinicalTrials.gov

7. Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

   This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cance…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mayo Clinic Hospital in Arizona, Phoenix, Arizona

   Locations

   75 in total

   Run by

   Canadian Cancer Trials Group

   See if you can join NCT06686771 on ClinicalTrials.gov

8. A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

   The researchers are doing this study to find out whether ivonescimab in combination with datopotamab deruxtecan- (Dato-DXd) or osimertinib are safe and effective treatments in people with non-small cell lung cancer (NSCLC) that has an EGFR mutation. The researchers will test different doses of the …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07535437 on ClinicalTrials.gov

9. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

   The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Rocky Mountain Cancer Center, Littleton, Colorado

   Locations

   28 in total

   Run by

   Jazz Pharmaceuticals

   See if you can join NCT06695845 on ClinicalTrials.gov

10. LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

    This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change i…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, Davis, Sacramento, California

    Run by

    University of California, Davis

    See if you can join NCT06103682 on ClinicalTrials.gov

11. Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer

    The purpose of this study is to find out if fluid rinsed from peoples' airways (bronchial washing samples) during routine surgery to remove (resect) their non-small cell lung cancer (NSCLC) tumors contains enough vesicles to do testing that may help the researchers learn more about their NSCLC.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05424029 on ClinicalTrials.gov

12. A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

    The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal can…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber/Massachusetts General Hospital, Inc, Boston, Massachusetts

    Locations

    9 in total

    Run by

    PAQ Therapeutics, Inc.

    See if you can join NCT07300150 on ClinicalTrials.gov

13. A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

    This is a first-in-human (FIH) Phase I/II, multi-center, open-label, study of ANS02, in patients with advanced NSCLC. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS02 as monotherapy.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Fairfax, Virginia

    Locations

    5 in total

    Run by

    Avistone Biotechnology Co., Ltd.

    See if you can join NCT07538804 on ClinicalTrials.gov

14. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center /ID# 276272, Duarte, California

    Locations

    48 in total

    Run by

    AbbVie

    See if you can join NCT05005403 on ClinicalTrials.gov

15. A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

    This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute at HealthONE, Denver, Colorado

    Locations

    15 in total

    Run by

    IDEAYA Biosciences

    See if you can join NCT07503808 on ClinicalTrials.gov

16. Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer

    The purpose of this trial is to test a deescalated 3-fraction stereotactic body radiotherapy (SBRT) regimen to 45 Gray (Gy) in 3 fractions for centrally located thoracic tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Smilow Cancer Hospital Care Center at Greenwich, Greenwich, Connecticut

    Locations

    6 in total

    Run by

    Yale University

    See if you can join NCT04210492 on ClinicalTrials.gov

17. IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

    In Cohort 1, the study was intended to assess safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab, in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung c…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    CHU de Limoges, Limoges,

    Locations

    30 in total

    Run by

    Innate Pharma

    See if you can join NCT05742607 on ClinicalTrials.gov

18. A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

    Current clinical trials testing the combination of immunotherapy with radiotherapy.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    o University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT07603856 on ClinicalTrials.gov

19. DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

    The purpose of this study, known as DISCERN, is to compare two different treatments for a type of lung cancer called non-small cell lung cancer (NSCLC) that does not show a marker known as PD-L1. This study will help us understand if using two types of immune therapy together with chemotherapy is b…

    Stage

    Phase 2

    Ages

    18 to 89

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT06364917 on ClinicalTrials.gov

20. A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

    The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesotheli…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Banner Health, Gilbert, Arizona

    Locations

    12 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT06051695 on ClinicalTrials.gov

21. MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

    This is a multipart, open-label, multi-center dose escalation, dose expansion phase I clinical trial designed to evaluate the safety, tolerability, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), and preliminary efficacy of MEM-288 in patients with advanced solid tumors. Eligible sub…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    2 in total

    Run by

    Memgen, Inc.

    See if you can join NCT05076760 on ClinicalTrials.gov

22. A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

    The purpose of this study is to investigate the study drug, OKN4395, administered alone and in combination with pembrolizumab. The overall objectives of this study are to determine the safety and tolerability (degree to which side effects of a drug can be tolerated) of OKN4395 alone and in combinat…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Precision NextGen Oncology and Research Center, Beverly Hills, California

    Locations

    10 in total

    Run by

    Epkin

    See if you can join NCT06789172 on ClinicalTrials.gov

23. Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

    The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine the…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

    Run by

    Abramson Cancer Center at Penn Medicine

    See if you can join NCT04332367 on ClinicalTrials.gov

24. Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

    The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or sp…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Rochester, Rochester, New York

    Locations

    2 in total

    Run by

    University of Rochester

    See if you can join NCT04297605 on ClinicalTrials.gov

25. Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

    This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Pioneer Research Center, LLC, Bullhead City, Arizona

    Locations

    15 in total

    Run by

    Genelux Corporation

    See if you can join NCT06463665 on ClinicalTrials.gov